Skip to main content

Angina Pectoris

9
Pipeline Programs
14
Companies
12
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
1
1
5
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

14 companies ranked by most advanced pipeline stage

Kite Pharma
Kite PharmaCA - El Segundo
2 programs
2
RanolazinePhase 4
RanolazinePhase 4
ViiV Healthcare
ViiV HealthcareNC - Durham
2 programs
2
RosiglitazonePhase 4
RosiglitazonePhase 4
Medtronic
MedtronicNJ - Phillipsburg
1 program
1
Spinal Cord StimulationPhase 41 trial
Active Trials
NCT00157742Terminated66Est. Jan 2007
Servier
ServierFrance - Suresnes
1 program
1
IvabradinePhase 31 trial
Active Trials
NCT00202566Completed750Est. Oct 2007
InfraReDx
InfraReDxMA - Bedford
1 program
1
Near Infrared SpectroscopyPhase 2/31 trial
Active Trials
NCT00330928Completed106Est. Oct 2008
MSD
MSDIreland - Ballydine
1 program
1
telcagepantPhase 11 trial
Active Trials
NCT01294709Completed64Est. Mar 2009
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
telcagepantPhase 1
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
3 programs
RanolazinePHASE_41 trial
RanolazinePHASE_4
RanolazinePHASE_41 trial
Active Trials
NCT01425359Completed949Est. Oct 2012
NCT01334203Withdrawn0Est. Dec 2012
VahatiCor
VahatiCorCA - Santa Clara
1 program
A-FLUX Reducer SystemN/A1 trial
Active Trials
NCT07449325Not Yet Recruiting30Est. Dec 2027
Shockwave Medical
Shockwave MedicalCA - Santa Clara
1 program
Reducer SystemN/A1 trial
Active Trials
NCT02710435Active Not Recruiting400Est. Dec 2028
Meril
MerilIndia - Vapi
1 program
Sirolimus Eluting Coronary Stent SystemN/A1 trial
Active Trials
NCT02901353Unknown400Est. Dec 2022
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
Tele-medicine platformN/A1 trial
Active Trials
NCT04325867UnknownEst. Oct 2020
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Lacidipine, low dosePHASE_21 trial
Active Trials
NCT02232607Completed283
GSK
GSKLONDON, United Kingdom
1 program
RosiglitazonePHASE_41 trial
Active Trials
NCT00225342Withdrawn60

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Gilead SciencesRanolazine
Gilead SciencesRanolazine
MedtronicSpinal Cord Stimulation
ServierIvabradine
InfraReDxNear Infrared Spectroscopy
Boehringer IngelheimLacidipine, low dose
MSDtelcagepant
VahatiCorA-FLUX Reducer System
T-TherapeuticsTele-medicine platform
MerilSirolimus Eluting Coronary Stent System
Shockwave MedicalReducer System

Clinical Trials (12)

Total enrollment: 3,108 patients across 12 trials

NCT00225342GSKRosiglitazone

Study Protocol for Rosiglitazone Versus Gliclazide in Diabetics With Angina

60 patients
Phase 4Withdrawn
NCT01425359Gilead SciencesRanolazine

Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina

Start: Sep 2011Est. completion: Oct 2012949 patients
Phase 4Completed
NCT01334203Gilead SciencesRanolazine

A Study on the Effects of Ranolazine on Exercise Duration in Subjects With Chronic Stable Angina and Coronary Artery Disease (CAD) With Type 2 Diabetes Mellitus (T2DM)

Start: May 2011Est. completion: Dec 20120
Phase 4Withdrawn
NCT00157742MedtronicSpinal Cord Stimulation

Comparison of SCS and PMR in Patients With Refractory Angina Pectoris

Start: Sep 2000Est. completion: Jan 200766 patients
Phase 4Terminated
NCT00202566ServierIvabradine

Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris

Start: Jun 2005Est. completion: Oct 2007750 patients
Phase 3Completed
NCT00330928InfraReDxNear Infrared Spectroscopy

SPECTACL: SPECTroscopic Assessment of Coronary Lipid

Start: Jan 2006Est. completion: Oct 2008106 patients
Phase 2/3Completed
NCT02232607Boehringer IngelheimLacidipine, low dose

Efficacy and Safety of Lacidipine in Chronic Stable Angina

Start: Apr 1998283 patients
Phase 2Completed
NCT01294709MSDtelcagepant

A Study to Assess the Safety, Tolerability, and Effects of MK-0974 (Telcagepant) on Exercise Tolerance in Patients With Stable Angina (MK-0974-014)

Start: Feb 2008Est. completion: Mar 200964 patients
Phase 1Completed
NCT07449325VahatiCorA-FLUX Reducer System

Self Expanding Coronary Sinus Reducer for Treatment of Symptomatic Coronary Microvascular Dysfunction (CMD)

Start: Apr 2026Est. completion: Dec 202730 patients
N/ANot Yet Recruiting
NCT04325867T-TherapeuticsTele-medicine platform

Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19

Start: Mar 2020Est. completion: Oct 2020
N/AUnknown
NCT02901353MerilSirolimus Eluting Coronary Stent System

A Prospective, Single-arm, Multi-centre, Observational, Real World Registry

Start: Feb 2017Est. completion: Dec 2022400 patients
N/AUnknown
NCT02710435Shockwave MedicalReducer System

REDUCER-I: An Observational Study of the Neovasc Reducer™ System

Start: Mar 2016Est. completion: Dec 2028400 patients
N/AActive Not Recruiting

Related Jobs

Clinical Research Scientist - VahatiCor

VahatiCorVahatiCor
Santa Clara, California, United States
1mo ago
$144K - $195K/yr

Product Development Manager - Advanced NanoTherapies (ANT)

VahatiCorVahatiCor
Cleveland, Ohio, United States
1mo ago
$115K - $136K/yr

Field Clinical Engineer - VahatiCor

VahatiCorVahatiCor
Santa Clara, California
2mo ago
$136K - $184K/yr

Manufacturing Operator - Advanced NanoTherapies

VahatiCorVahatiCor
Cleveland, Ohio
2mo ago
$20 - $25/hr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
14 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.